We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+9.84%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$15.7B
AUM Growth
+$958M
Cap. Flow
-$459M
Cap. Flow %
-2.93%
Top 10 Hldgs %
22.96%
Holding
925
New
41
Increased
262
Reduced
364
Closed
130

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$97.5M
2
PYPL icon
PayPal
PYPL
+$66.8M
3
HOLX
Hologic
HOLX
+$44.4M
4
BNTX icon
BioNTech
BNTX
+$35M
5
TMO icon
Thermo Fisher Scientific
TMO
+$34.3M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$80.5M
2
XLRN
Acceleron Pharma
XLRN
+$79.5M
3
AAPL icon
Apple
AAPL
+$55.8M
4
ONC
BeOne Medicines Ltd
ONC
+$44.9M
5
VZ icon
Verizon
VZ
+$37.9M

Sector Composition

Rank Sector Weight
1 Healthcare 31.29%
2 Technology 26.69%
3 Financials 8.86%
4 Communication Services 7.82%
5 Consumer Discretionary 7.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KLIC icon
801
Kulicke & Soffa
KLIC
$4.76B
– –
-99,098
Closed -$5.78M
LIN icon
802
Linde
LIN
$236B
– –
-5
Closed -$1K
LIT icon
803
Global X Lithium & Battery Tech ETF
LIT
$1.46B
– –
-2,624
Closed -$215K
LMND icon
804
Lemonade
LMND
$4.77B
– –
-5,500
Closed -$369K
LW icon
805
Lamb Weston
LW
$7.51B
– –
-11,455
Closed -$703K
MAC icon
806
Macerich
MAC
$7.52B
– –
-380,634
Closed -$6.36M
MDT icon
807
Medtronic
MDT
$111B
– –
-51
Closed -$6K
MHK icon
808
Mohawk Industries
MHK
$7.14B
– –
-9,531
Closed -$1.69M
MKL icon
809
Markel Group
MKL
$25.5B
– –
-388
Closed -$464K
MRUS
810
DELISTED
Merus
MRUS
– –
-47
Closed -$1K
NGD
811
DELISTED
New Gold Inc
NGD
– –
-109,650
Closed -$116K
NVCR icon
812
NovoCure
NVCR
$1.89B
– –
-3
Closed –
NVO
813
Novo Nordisk
NVO
$225B
– –
-46
Closed -$2K
ORA icon
814
Ormat Technologies
ORA
$6.05B
– –
-17,755
Closed -$1.18M
PACB icon
815
Pacific Biosciences
PACB
$432M
– –
-280,431
Closed -$7.17M
REMX icon
816
VanEck Rare Earth/Strategic Metals ETF
REMX
$1.95B
– –
-10,210
Closed -$1.05M
RGEN icon
817
Repligen
RGEN
$8.2B
– –
-14,064
Closed -$4.06M
RIO icon
818
Rio Tinto
RIO
$149B
– –
-27
Closed -$2K
SAGE
819
DELISTED
Sage Therapeutics
SAGE
– –
-185,058
Closed -$8.2M
SAM icon
820
Boston Beer
SAM
$1.93B
– –
-703
Closed -$358K
SEM
821
DELISTED
Select Medical
SEM
– –
-167,081
Closed -$4.04M
SLG icon
822
SL Green Realty
SLG
$3.77B
– –
-4,965
Closed -$352K
SMFG icon
823
Sumitomo Mitsui Financial
SMFG
$163B
– –
-138
Closed -$1K
SOXX icon
824
iShares Semiconductor ETF
SOXX
$40.6B
– –
-4,410
Closed -$655K
SPWH icon
825
Sportsman's Warehouse
SPWH
$45.7M
– –
-709,064
Closed -$12.5M
31 32
33
34 35

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q4 2021 Portfolio in Review

As of Q4 2021, Candriam SCA held 925 positions worth $15.7B, up 6.5% from $14.7B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Candriam SCA's Q4 2021 filing shows 41 new, 262 increased, 364 reduced and 130 closed positions. Its largest new stake was Couchbase: 858,038 shares worth $21.4M. The largest sale was Merck, an estimated $80.5M.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 32% a quarter earlier, followed by Technology and Financials.

  • Candriam SCA's largest Q4 2021 buy was Couchbase: 858,038 shares worth $21.4M.
  • Candriam SCA added most to Eli Lilly in Q4 2021, an estimated $97.5M increase.
  • Candriam SCA's biggest Q4 2021 reduction was Merck, cutting an estimated $80.5M.
  • Candriam SCA fully exited Acceleron Pharma in Q4 2021, selling an estimated $79.5M.
  • Candriam SCA's ten largest holdings make up 23% of its $15.7B portfolio in Q4 2021.
  • Candriam SCA opened 41 new positions and closed 130 in Q4 2021.
  • Candriam SCA's portfolio value rose 6.5% quarter-over-quarter to $15.7B.

Based on Candriam SCA's 13F filing for Q4 2021, filed 10 Feb 2022.